Under the reshuffle of the Chinese medicine injection market, where is the way out?

Traditional Chinese medicine injection is the product of the combination of traditional medicine theory and modern production technology
.
In the past, China's traditional Chinese medicine injection industry developed rapidly, but with the emergence of product quality and safety issues, the restrictions on traditional Chinese medicine injections have continued to tighten in recent years, and the performance of related companies has been under significant pressure
.
So, under the reshuffle of the Chinese medicine injection market, where is the way out? Under the reshuffle of the Chinese medicine injection market, where is the way out? (Image source: Pharmaceutical Network) The Chinese medicine injection market is undergoing a major reshuffle.
Since 2017, China's Chinese medicine injection industry has continued to be restricted by product use, listed in the key monitoring catalog, new medical insurance restricted use, key monitoring, clinical pathways, cancellation of outpatient clinics The market is undergoing a major reshuffle under the influence of infusion and other policies.
In recent years, the performance of related companies including Livzon Group, Dali Pharmaceutical, Kunyao Group and other related companies has experienced a sharp decline in overall performance, and life is quite difficult
.
Since 2021, the State Food and Drug Administration has continued to strengthen supervision measures such as monitoring of adverse reactions of traditional Chinese medicine injections and revising instructions
.
Among them, with regard to the efficacy and quality of TCM injection-related products, the State Drug Administration has issued relevant policies on the re-evaluation of TCM injections after they are marketed.
The industry pointed out that once TCM injections are marketed and the evaluation starts, the market will undoubtedly be shuffled further.
Intensify
.
In general, with the tightening of policies, the living space of Chinese medicine injection companies has become smaller and smaller
.
Some people in the industry have pointed out that it is expected that the decline of Chinese medicine injections will continue to expand in the future
.
Where is the way out? So, where is the way out for Chinese medicine injections? Judging from industry recommendations and actions of related companies, they are mainly reflected in two directions
.
First, focus on innovation
.
The limited use of traditional Chinese medicine injections is mainly related to safety and quality issues
.
At present, China's traditional Chinese medicine injection industry is developing rapidly, but the product quality is uneven.
The industry believes that only innovation can be a way out for listed companies
.
Only by strengthening the investment in innovative research and development, continuously carrying out evidence-based medicine clinical re-evaluation and basic research and achieving substantial results, can we provide a guarantee for products to gain a foothold in the market
.
"The future of Chinese medicine injections will return to clinical needs
.
For example, through cooperation with Zhejiang University, Kangyuan Pharmaceutical has strengthened the quality management of injections and controlled the entire
production process of injections .
It has built a real-time communication and data platform that is interoperable and integrated with production process control and production management systems.
The realization of a high degree of integration of industrialization and informatization "informatization and industrialization" has provided a demonstration for the "Made in China 2025" of traditional Chinese medicine injections
.
Second, active transformation
.
For example, China Resources 39 and Buchang Pharmaceuticals have already started the road of transformation, of which China Resources Three Nine mentioned in the 2018 semi-annual report that in recent years, under the pressure of the auxiliary drug catalog policy and bidding price reduction, the sales and promotion of non-clinical first-line drugs such as traditional Chinese medicine injections have faced difficulties.
The company continues to adjust the product structure and gradually The two ends of health preservation and rehabilitation
.
After adjustments in recent years, the company's product structure has become increasingly reasonable, and the proportion of traditional Chinese medicine injections, which originally accounted for a large part of the prescription drug business, in operating income has gradually declined
.
Another example is Kunyao Group.
In recent years, under the circumstances of major changes in national medical insurance policies and industry policies, the transformation of “injection-oral” and “prescription-retail” has begun
.
In the first half of 2021, the overall growth rate of the company’s oral products was 29%, and oral products accounted for The proportion of industrial revenue is 72%, which has exceeded the contribution of the previous core business injection sector
.
At the same time, oral products have also achieved significant growth in the retail end
.